Healthcare / BiotechnologyKOSDAQ
$706.00
+33.00 (+4.90%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-1.6B · quality 50.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$27.6B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-42.7%
↓Gross Margin
16.5%
↓Debt/Equity
0.22
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-20.1%
FCF CAGR
—
FCF margin
-55.1%
FCF / Net income
0.47x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $11.22B · net income $-13.05B · FCF $-6.18B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $11.22B | $11.22B | $15.63B | $18.25B | $22.00B |
| Net Income | $-13.05B | $-13.05B | $-6.99B | $8.01B | $-23.14B |
| EBITDA | $-9.53B | $-9.53B | $-3.35B | $1.83B | $-4.32B |
| EPS | -340.00 | -340.00 | -192.00 | 218.00 | -802.00 |
| Gross Margin | 16.5% | 16.5% | 29.4% | 30.6% | 31.4% |
| Operating Margin | -58.2% | -58.2% | -35.4% | -28.3% | -42.6% |
| Net Margin | -116.4% | -116.4% | -44.7% | 43.9% | -105.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.22 | 0.22 | 0.41 | 0.20 | 2.47 |
| Current Ratio | 13.79 | 13.79 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-6.18B | $-6.18B | $-1.56B | $5.80B | $-22.40B |
| Returns | |||||
| ROE | -42.7% | -42.7% | -18.7% | 24.3% | -106.7% |
| Valuation | |||||
| P/E | — | — | — | 9.54 | — |
| EV/EBITDA | — | — | — | 35.08 | — |
| P/B | 0.89 | 0.89 | 1.28 | 2.32 | 5.21 |
| Growth & Yield | |||||
| Revenue Growth | -28.2% | -28.2% | -14.3% | -17.1% | — |
| EPS Growth | -77.1% | -77.1% | -188.1% | 127.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-45.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-192.00 → -340.00
Residual
-45.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.